Most Read Articles
Pearl Toh, 26 Jun 2020
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Audrey Abella, 07 Oct 2019
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final r­esults of the EXCEL* trial presented at TCT 2019.

Unfractionated heparin for venous thromboembolism ups risk of bleeding in obese patients

4 days ago

In morbidly obese hospitalized patients, high-fixed dose unfractionated heparin for the prevention of venous thromboembolism is associated with a higher risk of major bleeding events compared with high-fixed dose enoxaparin, a recent study has shown.

Of the 305 patients included, 190 received unfractionated heparin and 115 enoxaparin. The incidence of major bleeding was significantly higher among patients on unfractionated heparin (odds ratio [OR], 1.85, 95 percent confidence interval [CI], 1.07–3.13; p=0.025). No significant difference was seen in the incidence of venous thromboembolism diagnosed during hospitalization.

Intensive care acuity (OR, 3.32, 95 percent CI, 1.91–5.78; p<0.001) and selection of unfractionated heparin rather than enoxaparin for venous thromboembolism prophylaxis (OR, 2.16, 95 percent CI, 1.22–3.82; p=0.008) were independently predictive of major bleeding.

In this single-centre retrospective, observational study, the authors identified hospitalized patients who were morbidly obese (body mass index, ≥40 kg/m2) and who received either high-fixed dose enoxaparin (40 mg every 12 hours) or unfractionated heparin (7,500 units every 8 hours) for venous thromboembolism prophylaxis.

Incidence of major bleeding and venous thromboembolism diagnosed during hospitalization were the co-primary endpoints. Multivariable regression was used to determine the predictors of major bleeding.

“Venous thromboembolism is a cause of morbidity and mortality in hospitalized patients, and morbid obesity increases this risk,” the authors said.

“Various prophylaxis dosing strategies have been investigated, [but] it [was] unclear if high-fixed dose enoxaparin or high-fixed dose unfractionated heparin thromboprophylaxis [was] optimal for minimizing the incidence of major bleeding and reducing hospital-acquired venous thromboembolism,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 26 Jun 2020
The prescription omega-3 fatty acid icosapent ethyl significantly reduces the need for revascularization in patients with elevated triglycerides who were already on statins and were at increased cardiovascular (CV) risk, reveals the latest data from the REDUCE-IT REVASC analysis presented during the SCAI* 2020 Meeting.
Audrey Abella, 07 Oct 2019
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final r­esults of the EXCEL* trial presented at TCT 2019.